[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Long term immunity, looking good", "description": "Immunological memory to SARS-CoV-2 assessed for greater than six months after infection \n\n(16th November, Institute for Immunology CA, and University of California) \n\nhttps://www.biorxiv.org/content/10.1101/2020.11.15.383323v1\n\nHumans make:\n\nSARS-CoV-2-specific antibodies\n\nCD4+ T cells (helpers)\n\nCD8+ T cells (killers)\n\nMemory B cells\n\nNeutralizing antibodies have generally not correlated with lessened COVID-19 disease severity\n\nPassive prophylactic antibodies limits disease in animals\n\nLess so after infection\n\nClinical hepatitis is prevented by vaccine-elicited immune memory even in the absence of circulating antibodies\n\nSix months or more is usually required to ascertain the durability of immune memory\n\nCross-sectional study\n\nN = 185 \n\n41 cases, more than 6 months \n\nRecovered COVID-19 cases\n\n43% male, 57% female\n\nMild, moderate, and severe COVID-19 cases\n\nMultiple sites throughout the United States\n\n92% of subjects were never hospitalized\n\n7% of subjects were hospitalized\n\n97% symptomatic\n\nResults, B cells\n\nSpike IgG was relatively stable over 6+ months\n\nSpike-specific memory B cells were more abundant at 6 months than at 1 month\u2026\n\ndetected in almost all COVID-19 cases\n\nNo apparent half-life at 5+ months post-infection\n\nSmallpox vaccine, 60+ years\n\nInfluenza infection, 90 years\n\nResults, T cells\n\nSARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a half-life of 3-5 months\n\nDecay of circulating SARS-CoV-2- specific CD8+ T cell is consistent with what has been reported for another acute virus\n \nSmallpox also uses CD4+ T cells, t1/2 of ~10 years\n\nT cell memory might reach a more stable plateau, or slower decay phase, later than the first 6 months post-infection. \n\nEach component of SARS-CoV-2 immune memory exhibited distinct kinetics\n\nImmunity and reinfection\n\nMemory B and T cell responses can take 3-5 days to successfully respond to an infection \n\nSARS-CoV T cells 17 years after the initial infection\n\nSARS-CoV, MERS-CoV, and SARS-CoV-2 are all betacoronaviruses \n\nhttps://www.cell.com/immunity/pdf/S1074-7613(20)30312-5.pdf\n\nSARS-CoV-2 is most similar to SARS-CoV-1\n\nFollowed by MERS-CoV (2012)\n\nhttps://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.full.pdf\n\nIf you would like to donate to this educational project, please use the following link, thank you, https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=78GGHGLK5ZXAE\n\nIt doesn't matter that we were all doing social distancing, it doesn't matter that I'm fit as a butcher's dog, feel great  \u2013 so many people do in my circumstances. \nAnd actually it doesn't matter that I've had the disease and I'm bursting with antibodies.\nWe've got to interrupt the spread of the disease\u2026and one of the ways we can do that now is by self isolating for 14 days when contacted by Test and Trace.\n\nIf you would like to donate to this educational project, please use the following link, thank you, https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=78GGHGLK5ZXAE", "link": "https://www.youtube.com/watch?v=gFeJ2BqCFY0", "date_published": "2020-11-18 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Vaccine, looking very good", "description": "Pfizer / BioN Tech vaccine, what we know\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine\n\nHTTPS://WWW.BUSINESSWIRE.COM/NEWS/HOME/20201118005595/EN/\n\nPFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 VACCINE CANDIDATE, MEETING ALL PRIMARY EFFICACY ENDPOINTS\n\nWednesday, November 18, 2020 - 06:59am \n\nPhase 3, 27th July\n\nPrimary efficacy analysis, 95% effective\n\n(p less than 0.0001), 9, 999 out of 10,000\n\nhigh rate of protection against COVID-19 can be achieved very fast after the first 30 \u00b5g dose\n\nbeginning 28 days after the first dose\n\n170 confirmed case\n\n10 severe cases\n\nN = 41,135\n\n42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds\n\n41% of global and 45% of U.S. participants are 56-85 years of age\n\nPlacebo group\n\n162 infections\n\n9 severe cases\n\nVaccine group\n\n8 infections\n\n1 severe case\n\nEfficacy was consistent across age, gender, race and ethnicity demographics\n\nObserved efficacy in adults over 65 years of age was over 94%\n\nTwo month safety test\n\nSafety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use \n\nAuthorization (EUA) has been achieved\n\nSide effects\n\nFDA adverse events rules\n\nhttps://www.fda.gov/media/73679/download\n\nWell tolerated across all populations\n\nNo serious safety concerns observed\n\nMostly less than 2%\n\nGrade 3 adverse event \n\nFatigue 3.8% \n\nHeadache 2.0%\n\nPlan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe\n\nexpect to produce globally up to 50 million vaccine doses in 2020\n\n1.3 billion doses by the end of 2021\n\nPfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world\n\nManufacturing\n\nGermany \n\nBelgium\n\n3 US sites\n\nLogistics\n\nSpecially designed, temperature-controlled thermal shippers\n\nUtilizing dry ice\n\nMaintain temperature conditions of -70\u00b0C\u00b110\u00b0C\n\nThey can be used be as temporary storage units for 15 days by refilling with dry ice\n\nUK\n40 million doses, 10 million by end of the year", "link": "https://www.youtube.com/watch?v=8Kb1exHnDcQ", "date_published": "2020-11-18 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]